SAB Biotherapeutics, Inc. SEC filings SABS
SAB Biotherapeutics, Inc. has 433 filings in SEC EDGAR's recent list, going back to Dec 7, 2020. Its latest annual report, Form 10-K, was filed on Mar 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 13, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 25-NSE | Delisting notice | Oct 22, 2026 | — |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 424B3 | Prospectus | Aug 21, 2026 | — |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 7, 2026 | Jul 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement
|
May 4, 2026 | Apr 28, 2026 |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 22, 2026 | Apr 22, 2026 |
| S-8 | Employee stock plan registration | Mar 31, 2026 | — |
| 8-K |
Current report
Material agreement, Other events
|
Mar 19, 2026 | Mar 17, 2026 |
| 424B5 | Prospectus supplement | Mar 19, 2026 | — |
| 424B5 | Prospectus supplement | Mar 17, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 10, 2026 | Mar 10, 2026 |
| 10-K | Annual report | Mar 9, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| EFFECT | Filing | Jan 7, 2026 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 7, 2026 | Jan 5, 2026 |
| CORRESP | Letter to the SEC | Jan 5, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 2, 2026 | — |
| S-3 | Shelf registration | Dec 29, 2025 | — |
| 8-K |
Current report
Other events
|
Dec 29, 2025 | Dec 29, 2025 |
| S-8 | Employee stock plan registration | Dec 15, 2025 | — |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 424B3 | Prospectus | Nov 12, 2025 | — |
| EFFECT | Filing | Sep 30, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Sep 30, 2025 | Sep 30, 2025 |
| CORRESP | Letter to the SEC | Sep 26, 2025 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 26, 2025 | Sep 26, 2025 |
| S-3/A | Filing | Sep 22, 2025 | — |
| CORRESP | Letter to the SEC | Sep 22, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 15, 2025 | — |
| S-3 | Shelf registration | Sep 2, 2025 | — |
| DEF 14A | Proxy statement | Aug 29, 2025 | Sep 26, 2025 |
| PRE 14A | Preliminary proxy statement | Aug 19, 2025 | Aug 19, 2025 |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| D | Filing | Aug 5, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change, Other events
|
Jul 21, 2025 | Jul 21, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jul 17, 2025 | Jul 17, 2025 |
| DEF 14A | Proxy statement | Jun 2, 2025 | Jul 17, 2025 |
| 10-Q | Quarterly report | May 9, 2025 | Mar 31, 2025 |
| S-8 | Employee stock plan registration | Apr 3, 2025 | — |
| 10-K | Annual report | Mar 31, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets
|
Feb 5, 2025 | Jan 30, 2025 |
| 8-K |
Current report
Other events
|
Jan 28, 2025 | Jan 28, 2025 |
| 10-Q | Quarterly report | Nov 6, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2024 | Sep 9, 2024 |
| S-8 | Employee stock plan registration | Aug 12, 2024 | — |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 31, 2024 | Jul 26, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 27, 2024 | Jun 27, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 31, 2024 | May 26, 2024 |
| DEF 14A | Proxy statement | May 30, 2024 | May 22, 2024 |
| 8-K |
Current report
Other events
|
May 21, 2024 | May 21, 2024 |
| 10-Q | Quarterly report | May 20, 2024 | Mar 31, 2024 |
| NT 10-Q | Filing | May 15, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 8, 2024 | May 3, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 15, 2024 | Apr 12, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 29, 2024 | Mar 29, 2024 |
| 10-K | Annual report | Mar 29, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Mar 8, 2024 | Mar 5, 2024 |
| S-8 | Employee stock plan registration | Feb 23, 2024 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 2, 2024 | Jan 30, 2024 |
| 8-K |
Current report
Material agreement
|
Jan 26, 2024 | Jan 26, 2024 |
| 424B5 | Prospectus supplement | Jan 26, 2024 | — |
| 8-K |
Current report
Other events
|
Jan 25, 2024 | Jan 23, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 19, 2024 | Jan 19, 2024 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure
|
Jan 3, 2024 | Jan 2, 2024 |
| DEF 14A | Proxy statement | Dec 18, 2023 | Dec 18, 2023 |
| PRE 14A | Preliminary proxy statement | Dec 8, 2023 | Dec 8, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 29, 2023 | Nov 29, 2023 |
| EFFECT | Filing | Nov 28, 2023 | — |
| CORRESP | Letter to the SEC | Nov 24, 2023 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Nov 22, 2023 | Nov 22, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 20, 2023 | Nov 14, 2023 |
| S-3/A | Filing | Nov 20, 2023 | — |
| DEFA14A | Additional proxy material | Nov 14, 2023 | — |
| 8-K/A |
Amended current report
Unregistered share sale, Other events
|
Nov 14, 2023 | Sep 29, 2023 |
| 10-Q | Quarterly report | Nov 13, 2023 | Sep 30, 2023 |
| UPLOAD | Letter from the SEC | Nov 7, 2023 | — |
| S-3 | Shelf registration | Nov 3, 2023 | — |
| DEF 14A | Proxy statement | Oct 30, 2023 | Oct 30, 2023 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Oct 27, 2023 | Oct 23, 2023 |
| PRE 14A | Preliminary proxy statement | Oct 20, 2023 | Oct 20, 2023 |
| D | Filing | Oct 16, 2023 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Other events
|
Oct 2, 2023 | Sep 29, 2023 |
| UPLOAD | Letter from the SEC | Sep 27, 2023 | — |
| CORRESP | Letter to the SEC | Sep 26, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 25, 2023 | — |
| EFFECT | Filing | Aug 30, 2023 | — |
| CORRESP | Letter to the SEC | Aug 28, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2023 | — |
| S-3 | Shelf registration | Aug 21, 2023 | — |
| 8-K |
Current report
Auditor change
|
Aug 21, 2023 | Aug 18, 2023 |
| 10-Q | Quarterly report | Aug 21, 2023 | Jun 30, 2023 |
| NT 10-Q | Form nt 10-q | Aug 14, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Auditor change
|
Jul 31, 2023 | Jul 25, 2023 |
| AW | Form aw | Jul 31, 2023 | — |
| POS AM | Form pos am | Jul 10, 2023 | — |
| 8-K |
Current report
Shareholder vote results
|
Jul 3, 2023 | Jun 29, 2023 |
| RW | Form rw | Jun 21, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 21, 2023 | Jun 21, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 14, 2023 | Jun 14, 2023 |
| DEF 14A | Proxy statement | May 19, 2023 | Jun 29, 2023 |
| EFFECT | Filing | May 17, 2023 | — |
| 10-Q | Quarterly report | May 15, 2023 | Mar 31, 2023 |
| CORRESP | Letter to the SEC | May 15, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
May 12, 2023 | May 8, 2023 |
| UPLOAD | Letter from the SEC | May 12, 2023 | — |
| EFFECT | Filing | May 9, 2023 | — |
| S-3 | Shelf registration | May 9, 2023 | — |
| CORRESP | Letter to the SEC | May 5, 2023 | — |
| UPLOAD | Letter from the SEC | May 4, 2023 | — |
| S-3 | Shelf registration | May 1, 2023 | — |
| 10-K/A | Amended annual report | Apr 28, 2023 | Dec 31, 2021 |
| 10-K/A | Amended annual report | Apr 28, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 28, 2023 | Apr 26, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 19, 2023 | Apr 18, 2023 |
| 10-K | Annual report | Apr 14, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 14, 2023 | Apr 13, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 4, 2023 | Apr 3, 2023 |
| NT 10-K | Form nt 10-k | Mar 31, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations, Restatement
|
Mar 31, 2023 | Mar 30, 2023 |
| 8-K |
Current report
New debt, Unregistered share sale
|
Mar 24, 2023 | Mar 21, 2023 |
| 424B3 | Prospectus | Mar 7, 2023 | — |
| EFFECT | Filing | Feb 10, 2023 | — |
| EFFECT | Filing | Feb 8, 2023 | — |
| CORRESP | Letter to the SEC | Feb 8, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2023 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 7, 2023 | Feb 6, 2023 |
| S-3 | Shelf registration | Feb 3, 2023 | — |
| POS AM | Form pos am | Feb 3, 2023 | — |
| 8-K |
Current report
Listing notice
|
Jan 27, 2023 | Jan 23, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 10, 2023 | Jan 10, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 9, 2023 | Jan 9, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 5, 2023 | Jan 5, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Dec 12, 2022 | Dec 6, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 21, 2022 | Nov 21, 2022 |
| 424B3 | Prospectus | Nov 18, 2022 | — |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 7, 2022 | Nov 1, 2022 |
| 8-K |
Current report
Material agreement, Other events
|
Nov 1, 2022 | Oct 26, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Oct 13, 2022 | Oct 11, 2022 |
| 8-K |
Current report
Listing notice
|
Oct 7, 2022 | Oct 5, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 30, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 28, 2022 | Sep 27, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 23, 2022 | Sep 23, 2022 |
| S-1 | Registration statement | Aug 23, 2022 | — |
| 424B3 | Prospectus | Aug 17, 2022 | — |
| 10-Q | Quarterly report | Aug 10, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure, Other events
|
Jul 11, 2022 | Jul 6, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 5, 2022 | Jul 5, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 7, 2022 | Jun 7, 2022 |
| 424B3 | Prospectus | Jun 7, 2022 | — |
| 8-K |
Current report
Other events
|
Jun 6, 2022 | Jun 6, 2022 |
| DEF 14A | Proxy statement | May 25, 2022 | Jul 6, 2022 |
| 424B3 | Prospectus | May 16, 2022 | — |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| 424B3 | Prospectus | Apr 29, 2022 | — |
| EFFECT | Filing | Apr 26, 2022 | — |
| POS AM | Filing | Apr 20, 2022 | — |
| 10-K | Annual report | Mar 29, 2022 | Dec 31, 2021 |
| S-8 | Employee stock plan registration | Feb 1, 2022 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 10, 2022 | Jan 7, 2022 |
| 8-K |
Current report
Officer or director change
|
Jan 6, 2022 | Dec 31, 2021 |
| 424B3 | Prospectus | Dec 29, 2021 | — |
| EFFECT | Filing | Dec 15, 2021 | — |
| CORRESP | Letter to the SEC | Dec 13, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 8, 2021 | — |
| S-1 | Registration statement | Dec 3, 2021 | — |
| 8-K/A | Amended current report | Nov 22, 2021 | Oct 22, 2021 |
| 10-Q | Quarterly report | Nov 22, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations, Restatement
|
Nov 22, 2021 | Nov 22, 2021 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Nov 19, 2021 | Nov 17, 2021 |
| NT 10-Q | Filing | Nov 15, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change
|
Oct 28, 2021 | Oct 22, 2021 |
| 25-NSE | Delisting notice | Oct 22, 2021 | — |
| 8-K |
Current report
Shareholder vote results
|
Oct 21, 2021 | Oct 20, 2021 |
| 425 | Filing | Oct 13, 2021 | — |
| 8-K |
Current report
Other events
|
Oct 13, 2021 | Oct 12, 2021 |
| 425 | Filing | Oct 12, 2021 | — |
| 8-K |
Current report
Material agreement
|
Oct 12, 2021 | Oct 12, 2021 |
| 425 | Filing | Oct 7, 2021 | — |
| 425 | Filing | Oct 4, 2021 | — |
| 425 | Filing | Sep 28, 2021 | — |
| 425 | Filing | Sep 27, 2021 | — |
| 424B3 | Prospectus | Sep 24, 2021 | — |
| 424B3 | Prospectus | Sep 23, 2021 | — |
| EFFECT | Filing | Sep 22, 2021 | — |
| 425 | Filing | Sep 22, 2021 | — |
| CORRESP | Letter to the SEC | Sep 22, 2021 | — |
| S-4/A | Filing | Sep 22, 2021 | — |
| CORRESP | Letter to the SEC | Sep 21, 2021 | — |
| CORRESP | Letter to the SEC | Sep 16, 2021 | — |
| 425 | Filing | Sep 8, 2021 | — |
| CORRESP | Letter to the SEC | Sep 8, 2021 | — |
| S-4/A | Filing | Sep 8, 2021 | — |
| 425 | Filing | Sep 7, 2021 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SABS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami Beach, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1833214
- Former names
- Big Cypress Acquisition Corp. (until Oct 22, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.